Popular Trials
Alkylating agent
Veliparib + Topotecan ± Carboplatin for Leukemia
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial is studying the side effects and best dose of veliparib when given with topotecan hydrochloride and carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders.
Poly (ADP-ribose) polymerase (PARP) inhibitor
Pacritinib + Talazoparib for Myeloproliferative Disorders
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial is a study to find the appropriate dosage of talazoparib when given with pacritinib, a standard treatment. The goal is to determine the maximum tolerated dosage and the recommended
Curcumin Supplement for Myelodysplastic Syndrome and Myeloproliferative Disorders
Recruiting0 awardsPhase 2
Los Angeles, California
This trial looks at how a curcumin supplement can reduce inflammation and symptoms in patients with CCUS, LR-MDS, and MPN. Curcumin has anti-inflammatory and anti-cancer properties and has been studied for various diseases.
RNAi
SLN124 for Polycythemia Vera
Recruiting0 awardsPhase 1 & 2
The Woodlands, Texas
This trial is testing a new drug called SLN124 in adults with Polycythemia Vera, a condition where the body makes too many red blood cells. The study aims to see if SLN124 is safe and effective. Researchers will also look at how the drug moves through and affects the body.
JAK Inhibitor
MMB for Myelofibrosis
Recruiting1 awardPhase 2
Orange, California
This trial aims to provide ongoing access to momelotinib for patients with certain types of myelofibrosis who are already taking the drug and have not seen their disease get worse. The study will also look at how long these patients live without developing leukemia. Momelotinib has been studied for myelofibrosis and other related conditions.
Anti-metabolite
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Popular Filters
Trials for Myelofibrosis Patients
Antioxidant
N-Acetylcysteine for Myeloproliferative Disorders
Recruiting1 awardPhase 1 & 2
Orange, California
This trial is testing the best dose of N-acetylcysteine for patients with certain types of blood cancers. The medication helps reduce inflammation and protect cells, which might be beneficial for these patients. N-acetylcysteine (NAC) has been studied for its potential to prevent heart damage caused by certain cancer treatments and reduce flare-ups in chronic lung disease.
Anti-metabolites
Reduced-Intensity Conditioning for Blood Cancers
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial is looking at whether a less intense conditioning regimen of radiation therapy and chemotherapy prior to a hematopoietic stem cell transplant reduces the rate of treatment-related mortality.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Alkylating agents
Topotecan + Carboplatin + Veliparib for Leukemia
Recruiting1 awardPhase 2
Los Angeles, California
This trial is testing how well topotecan hydrochloride, carboplatin, and veliparib work in treating patients with myeloproliferative disorders and acute myeloid leukemia or chronic myelomonocytic leukemia.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Trials for PV Patients
Interferon
ECLIPSE PV / A22-203
Recruiting2 awardsPhase 3
New Orleans, Louisiana
This trial tests a medication called ropeginterferon alfa-2b-njft in adults with polycythemia vera, a type of blood cancer. The goal is to see how well it works and how safe it is. The medication helps the immune system control abnormal blood cells to prevent serious health issues. Ropeginterferon alfa-2b is a new form of treatment recently shown to be safe and effective in polycythemia vera.
Antioxidant
N-Acetylcysteine for Myeloproliferative Disorders
Recruiting1 awardPhase 1 & 2
Orange, California
This trial is testing the best dose of N-acetylcysteine for patients with certain types of blood cancers. The medication helps reduce inflammation and protect cells, which might be beneficial for these patients. N-acetylcysteine (NAC) has been studied for its potential to prevent heart damage caused by certain cancer treatments and reduce flare-ups in chronic lung disease.
Anti-metabolites
Reduced-Intensity Conditioning for Blood Cancers
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial is looking at whether a less intense conditioning regimen of radiation therapy and chemotherapy prior to a hematopoietic stem cell transplant reduces the rate of treatment-related mortality.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Hepcidin Mimetic
Hepcidin Mimetic for Polycythemia Vera
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial tests PTG-300, a new medication, in patients with polycythemia vera who need regular blood removal. PTG-300 aims to keep red blood cell levels in check, reducing the need for frequent blood removal.
Phase 3 Trials
Interferon
ECLIPSE PV / A22-203
Recruiting2 awardsPhase 3
New Orleans, Louisiana
This trial tests a medication called ropeginterferon alfa-2b-njft in adults with polycythemia vera, a type of blood cancer. The goal is to see how well it works and how safe it is. The medication helps the immune system control abnormal blood cells to prevent serious health issues. Ropeginterferon alfa-2b is a new form of treatment recently shown to be safe and effective in polycythemia vera.
Epigenetic Modulator
Bomedemstat for Blood Disorders
Recruiting2 awardsPhase 3
Ann Arbor, Michigan
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Small Molecule Inhibitor
KRT-232 for Myelofibrosis
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial will study KRT-232, a new drug that inhibits MDM2, for the treatment of patients with myelofibrosis who are no longer benefiting from treatment with a JAK inhibitor. The trial will be conducted in 2 phases.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
Recruiting2 awardsPhase 3
Commack, New York
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Trials With No Placebo
Interferon
ECLIPSE PV / A22-203
Recruiting2 awardsPhase 3
New Orleans, Louisiana
This trial tests a medication called ropeginterferon alfa-2b-njft in adults with polycythemia vera, a type of blood cancer. The goal is to see how well it works and how safe it is. The medication helps the immune system control abnormal blood cells to prevent serious health issues. Ropeginterferon alfa-2b is a new form of treatment recently shown to be safe and effective in polycythemia vera.
Antioxidant
N-Acetylcysteine for Myeloproliferative Disorders
Recruiting1 awardPhase 1 & 2
Orange, California
This trial is testing the best dose of N-acetylcysteine for patients with certain types of blood cancers. The medication helps reduce inflammation and protect cells, which might be beneficial for these patients. N-acetylcysteine (NAC) has been studied for its potential to prevent heart damage caused by certain cancer treatments and reduce flare-ups in chronic lung disease.
Anti-metabolites
Reduced-Intensity Conditioning for Blood Cancers
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial is looking at whether a less intense conditioning regimen of radiation therapy and chemotherapy prior to a hematopoietic stem cell transplant reduces the rate of treatment-related mortality.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.